Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for mirikizumab

  1. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    25 October 2023
    View recommendations

    Sections for TA925

  2. Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]

    In development [GID-TA11267] Expected publication date: 10 July 2025

    Technology appraisal guidance
    In development

  3. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: 30 July 2025

    Technology appraisal guidance
    In development

  4. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

    NICE guideline
    Published
    3 May 2019
    View recommendations

    Sections for NG130

  5. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals